These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 23763830)
21. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. Chen LL; Ye F; Lü WG; Yu Y; Chen HZ; Xie X J Obstet Gynaecol Res; 2009 Apr; 35(2):212-8. PubMed ID: 19335794 [TBL] [Abstract][Full Text] [Related]
22. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316 [TBL] [Abstract][Full Text] [Related]
23. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma. Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689 [TBL] [Abstract][Full Text] [Related]
24. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Zhu Q; Wu X; Wu Y; Wang X Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885 [TBL] [Abstract][Full Text] [Related]
25. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788 [TBL] [Abstract][Full Text] [Related]
26. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer. Li T; Xue H; Guo Y; Guo K Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179 [TBL] [Abstract][Full Text] [Related]
27. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362 [TBL] [Abstract][Full Text] [Related]
28. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients. Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246 [TBL] [Abstract][Full Text] [Related]
29. Gene expression and prognostic significance in ovarian cancer. Tammela J; Odunsi K Minerva Ginecol; 2004 Dec; 56(6):495-502. PubMed ID: 15729202 [TBL] [Abstract][Full Text] [Related]
30. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206 [TBL] [Abstract][Full Text] [Related]
31. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Zhang Z; Huang J; Zhang C; Yang H; Qiu H; Li J; Liu Y; Qin L; Wang L; Hao S; Zhang F; Wang X; Shan B Cancer Gene Ther; 2015 Mar; 22(4):198-206. PubMed ID: 25721210 [TBL] [Abstract][Full Text] [Related]
32. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921 [TBL] [Abstract][Full Text] [Related]
34. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380 [TBL] [Abstract][Full Text] [Related]
35. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Xia B; Yang S; Liu T; Lou G Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927 [TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Wahba J; Natoli M; Whilding LM; Parente-Pereira AC; Jung Y; Zona S; Lam EW; Smith JR; Maher J; Ghaem-Maghami S Cancer Immunol Immunother; 2018 Nov; 67(11):1753-1765. PubMed ID: 30167862 [TBL] [Abstract][Full Text] [Related]
37. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells. Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225 [TBL] [Abstract][Full Text] [Related]
38. Ovarian carcinoma glyco-antigen targeted by human IgM antibody. Chen Y; Bieber MM; Bhat NM; Teng NNH PLoS One; 2017; 12(12):e0187222. PubMed ID: 29267289 [TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer. Longoria TC; Eskander RN Recent Pat Anticancer Drug Discov; 2015; 10(2):133-44. PubMed ID: 25938471 [TBL] [Abstract][Full Text] [Related]
40. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Hou S; Du P; Wang P; Wang C; Liu P; Liu H Clin Transl Oncol; 2017 Sep; 19(9):1107-1116. PubMed ID: 28332091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]